BriaCell

▪ Clinical stage immuno-oncology company developing an entirely new class of targeted immunotherapies to transform cancer care

▪ Bria-IMT™, BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT™ is a targeted cell-based immunotherapy.

▪ Bria-OTS™, a platform of personalized off-the-shelf cell-based immunotherapies, is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.

▪ Bria-IMT - a cell based, patented, targeted immunotherapy
▪ Derived from a well characterized breast cancer cell line
▪ Expresses tumor antigens and GM-CSF to activate cancer fighting CD4+ and CD8+ T cells
▪ Stimulates the immune system to enhance targeted killing of cancer cells
▪ Off-the-shelf approach easy to distribute and administer

➢ Cell are grown (cGMP), harvested, irradiated and cryopreserved for shipment to clinical sites where they are thawed and injected intradermally (upper back and thighs)

▪ Lead drug candidate Bria-IMT™
➢ Pivotal Phase 3 study underway in metastatic breast cancer (over 40K US deaths/year)
➢ Phase 2 study demonstrated 2-fold increase in survival vs comparable patients in the literature
➢ Unprecedented clinical benefit in checkpoint inhibitor (CPI) and antibody-drug conjugate (ADC) resistant patients
➢ Remarkable clinical efficacy in patients with central nervous system (CNS) metastases
➢ Awarded Fast Track designation by FDA
➢ Single agent and combination check point inhibitor (+ CPI) activity

▪ Bria-OTS & Bria-OTS+ : Next generation, cell-based cancer immunotherapy platform
➢ Ongoing Phase 1/2a study in breast cancer
➢ Bucket trial with other cancer indications to be added
➢ Next generation prostate cancer candidate scheduled to enter clinic 2025
➢ National Cancer Institute SBIR awards
➢ Bria-OTS+ more potent version of Bria-OTS